Justin Baker, MD
Hematology & Oncology · Jackson, MSNPI 1639119589
Payments from drug & device makers
Across 183 payments — averaging $11,592 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2M
- E.r. Squibb & Sons, L.L.C.$72K
- Genentech, Inc.$2K
- Pfizer$2K
- Mirati Therapeutics, Inc.$1K
- Johnson & Johnson$418
- plus $2K from 35 others
What the payments were for
- Food & beverage$2,61698%
- Education$632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $2,041,267 |
| E.r. Squibb & Sons, L.L.C. | 8 | $72,476 |
| Genentech, Inc. | 5 | $2,241 |
| Pfizer | 19 | $2,086 |
| Mirati Therapeutics, Inc. | 1 | $1,000 |
| Johnson & Johnson(2 entities) | 29 | $418 |
| Bristol Myers Squibb | 19 | $345 |
| Deciphera Pharmaceuticals Inc. | 11 | $225 |
| Gilead(2 entities) | 9 | $182 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $101 |
| Astellas Pharma US Inc | 5 | $86 |
| AbbVie | 3 | $75 |
| Servier Pharmaceuticals LLC | 4 | $71 |
| Tersera Therapeutics LLC | 2 | $68 |
| Octapharma USA, Inc. | 3 | $55 |
| Array Biopharma Inc | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $48 |
| AstraZeneca | 3 | $48 |
| Bayer | 2 | $42 |
| Eisai Inc. | 2 | $41 |
| Karyopharm Therapeutics Inc. | 2 | $39 |
| Sanofi | 2 | $37 |
| Amgen | 2 | $32 |
| CTI Biopharma Corp. | 2 | $29 |
| Genentech USA, Inc. | 2 | $25 |
| Beigene USA, Inc. | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $21 |
| Inari Medical, Inc. | 1 | $21 |
| Secura Bio, Inc. | 2 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| GSK | 1 | $18 |
| Merck | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Celltrion USA Inc. | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $13 |
| Acera Surgical, Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $7 |
How this compares
$2,121,347 in reported general payments places this provider in the 95th percentile of 57 hematology & oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 84 | $1,271,881 |
| ImbruvicaIbrutinib | 61 | $812,061 |
| CabometyxCabozantinib S-Malate | 26 | $661,969 |
| InlytaAxitinib | 36 | $512,926 |
| NubeqaDarolutamide | 38 | $503,350 |
| CalquenceAcalabrutinib Maleate | 29 | $433,597 |
| BosulifBosutinib | 26 | $409,335 |
| IbrancePalbociclib | 23 | $371,298 |
| PomalystPomalidomide | 17 | $264,713 |
| SprycelDasatinib | 11 | $229,404 |
| XtandiEnzalutamide | 13 | $180,247 |
| JakafiRuxolitinib Phosphate | 14 | $62,150 |
| Imatinib Mesylate | 54 | $47,013 |
| EliquisApixaban | 65 | $44,562 |
| Abiraterone Acetate | 14 | $19,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Bosulif, Ibrance, Eliquis | $2,086 | $1,338,121150 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $101 | $812,06161 claims |
| BayerNubeqa | $42 | $503,35038 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $72,476 | $494,11728 claims |
| AstraZenecaCalquence | $48 | $433,59729 claims |
| Astellas Pharma US IncXtandi | $86 | $180,24713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 hematology & oncology providers in Mississippi.
Other hematology & oncology in Jackson
- John HeneganJackson$1.2M
- Carter MilnerJackson$261K
- Barbara CraftJackson$135K
- Guangzhi QuJackson$78K
- Bobby WilkersonJackson$28K
- Grace ShumakerJackson$10K
- Katherine ThielJackson$2K
- John HromHattiesburg$10M
- Solly ChedidPascagoula$1.7M
- Andrew KellumTupelo$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.